Hematology Frontier

From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. Based on the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers from the 2024 ASCO conference for comprehensive and in-depth interpretation. During the conference, "Oncology Frontier - Hematology Frontier" conducted an exclusive interview with Professor Tiejun Gong from the Harbin Institute of Hematology and Oncology. He shared his profound insights and unique academic perspectives on major studies presented at ASCO this year, the progress of the novel CD3 x CD19 IgG4 bispecific antibody CN201, and the overall status and future prospects of hematologic oncology treatment in China.

TP53 mutations not only profoundly affect the progression trajectory of chronic lymphocytic leukemia (CLL), but are also directly associated with poor prognosis, becoming an important factor that cannot be ignored when assessing disease severity and formulating personalized treatment strategies. At the highly anticipated 29th Annual Congress of the European Hematology Association (EHA 2024), Dr. Consuelo Bertossi from the Department of Internal Medicine III at the University of Ulm in Germany, through an exciting oral presentation, deeply analyzed the "The Landscape of TP53 Mutations and Their Prognostic Impact in Chronic Lymphocytic Leukemia (S101)", providing valuable data and insights for the attendees, which has important guiding value for clinical practice and scientific research exploration. To further discuss this cutting-edge topic, "Oncology Frontier-Hematology Frontier" specially invited Dr. Consuelo Bertossi for an interview on the spot, sharing the impact of TP53 mutations on survival rates, the efficacy of targeted drugs, and future research directions.

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Li Bao from Beijing Jishuitan Hospital for an exclusive interview to discuss advancements in the field and share academic insights.

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To capture the conference's dynamics and facilitate in-depth exchange, Oncology Frontier - Hematology Frontier invited Dr. Kai Hu from Beijing GoBroad Hospital for an exclusive interview. He provided insightful explanations on the topic of "The Application of Immunotherapy in Lymphoma/Myeloma."

On July 20, 2024, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. At this conference, Dr. Lin Fu from the Department of Hematology at Beijing Tiantan Hospital delivered an insightful presentation on the "Advances in Diagnosis and Treatment of Primary Central Nervous System Lymphoma (PCNSL)." To capture the conference's dynamics and facilitate in-depth exchange, Oncology Frontier - Hematology Frontier conducted an exclusive interview with Dr. Lin Fu. The following is a summary for readers' reference.

Acute promyelocytic leukemia (APL) is a highly aggressive hematological disease, and its treatment has long been a challenge in the field. Chinese scholars have contributed significantly to global APL treatment with the introduction of the arsenic trioxide (ATO) regimen. Since the publication of the APL0406 study in NEJM in 2013, the combination of all-trans retinoic acid (ATRA) and ATO has replaced ATRA combined with chemotherapy as the standard treatment for low- and intermediate-risk APL patients. However, whether this regimen is suitable for high-risk APL patients remains undetermined due to a lack of randomized controlled trials. At the 29th Annual Meeting of the European Hematology Association (EHA 2024) held from June 13-16, 2024, Dr. Uwe Platzbecker from the Leipzig University in Germany presented key findings from the APOLLO study. This study demonstrated that the combination of ATO and ATRA offers a new treatment strategy for high-risk APL patients, providing valuable insights into the current state of APL treatment and guiding future research directions and clinical practices. Oncology Frontier - Hematology Frontier invited Professor Platzbecker to share the important discoveries and clinical significance of the APOLLO study.

On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was grandly held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Xiaoyan Ke from the Peking University Third Hospital/Beijing GoBroad Hospital for an exclusive interview to discuss advancements in the field and share academic insights.

On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Jihao Zhou from Shenzhen People's Hospital for an exclusive interview to discuss advancements in the field and share academic insights.

Dr. Andreas Greinacher, with over 35 years of extensive experience, has brought groundbreaking scientific discoveries to the field of hematology through his critical thinking and relentless curiosity. At the highly anticipated 2024 International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting, he was awarded the prestigious Robert P. Grant Medal, showcasing his profound expertise and significant contributions to the field of thrombosis and hemostasis.

The International Society on Thrombosis and Haemostasis (ISTH) is an inclusive organization with a global perspective, providing a valuable platform for scholars from around the world to engage, interact, and collaborate. Dr. David Lillicrap, a professor in the Department of Pathology and Molecular Medicine at Queen's University in Canada, was honored with the Harold R. Roberts Award at the ISTH 2024 meeting. This award recognizes individuals who have steadfastly supported the mission of the ISTH Scientific and Standardization Committee (SSC) through selfless dedication and expertise. As an outstanding hematologist and researcher, Dr. Lillicrap enjoys high acclaim in the field and has held several leadership positions within ISTH, including the Chair of the ISTH SSC. The Roberts Award not only acknowledges his exceptional service to the ISTH SSC but also celebrates his extraordinary dedication and lasting contributions.